Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Microport NeuroTech (微创脑科学) Pre-IPO: Decent Name for Neuro-Interventional Devices

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Healthcare equipment and supplies / Quantitative Analysis

<ul>
<li>Microport NeuroTech is a leading neuro-interventional device company in China. The company launched a downsized deal to  raise up to USD 43m via a Hong Kong listing.</li>
<li>In our previous note, we looked at the company's key segments and products. We like the company's comprehensive coverage of neuro-interventional devices. Its management team has decent experience.</li>
<li>In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.</li>
</ul>


Microport NeuroTech is a leading neuro-interventional device company in China. The company launched a downsized deal to  raise up to USD 43m via a Hong Kong listing.
In our previous note, we looked at the company's key segments and products. We like the company's comprehensive coverage of neuro-interventional devices. Its management team has decent experience.
In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.


Microport NeuroTech (微创脑科学) IPO: Aggressive Valuation